DDI-DrugBank.d648.s0 >> Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. >> 0-13,16-29,101-110,150-155
DDI-DrugBank.d648.s1 >> Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. >> 0-7,34-39,45-52
DDI-DrugBank.d648.s2 >> However, 10% decreases in prothrombin time have been observed in single-dose studies.
DDI-DrugBank.d648.s3 >> If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. >> 3-8,37-44
DDI-DrugBank.d648.s4 >> Other Highly Protein-Bound Drugs: Raloxifene is more than 95% bound to plasma proteins. >> 34-43
DDI-DrugBank.d648.s5 >> In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. >> 10-19,51-58,61-69,75-83
DDI-DrugBank.d648.s6 >> Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. >> 28-33,100-109,112-123,126-133,136-144,147-154,161-169
DDI-DrugBank.d648.s7 >> See also CLINICAL PHARMACOLOGY, Drug-Drug Interactions
